Active Ingredient(s):Anifrolumab-fnia FDA Approved: * July 30, 2021 Pharm Company: *ASTRAZENECA AB Category:Immune System
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.[medical citation needed]
Anifrolumab was approved for medical use in the United States in August 2021.[5...
* May have multiple approval dates, manufacturers, or labelers.